CapsoVision, Inc. (NASDAQ:CV – Get Free Report) shot up 12.9% on Wednesday . The stock traded as high as $14.69 and last traded at $14.56. 68,205 shares were traded during mid-day trading, a decline of 58% from the average session volume of 163,778 shares. The stock had previously closed at $12.90.
Analysts Set New Price Targets
A number of analysts have recently commented on the company. Benchmark reissued a “speculative buy” rating on shares of CapsoVision in a research report on Friday, November 14th. Zacks Research upgraded shares of CapsoVision to a “hold” rating in a research note on Wednesday, November 5th. Roth Capital set a $7.00 target price on shares of CapsoVision in a report on Tuesday, November 4th. Finally, Weiss Ratings reissued a “sell (e)” rating on shares of CapsoVision in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, CapsoVision presently has an average rating of “Moderate Buy” and an average target price of $6.00.
CapsoVision Trading Up 4.4%
CapsoVision (NASDAQ:CV – Get Free Report) last posted its earnings results on Thursday, November 13th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The company had revenue of $3.54 million for the quarter.
Institutional Investors Weigh In On CapsoVision
An institutional investor recently bought a new position in CapsoVision stock. New York State Common Retirement Fund purchased a new stake in shares of CapsoVision, Inc. (NASDAQ:CV – Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 7,114 shares of the company’s stock, valued at approximately $34,000.
CapsoVision Company Profile
CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.
In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.
Read More
- Five stocks we like better than CapsoVision
- Trump’s $500B plan is fueling these monthly dividends
- Trump Did WHAT??
- Put $1,000 into this stock by Jan 1 [Not NVDA]
- How Long Will $1M Last in Retirement?
- [How To] Claim Your Pre-IPO Stake In SpaceX!
Receive News & Ratings for CapsoVision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CapsoVision and related companies with MarketBeat.com's FREE daily email newsletter.
